Resultats de la cerca - Anatole Besarab
- Mostrar 1 - 20 resultats de 31
- Anar a la pàgina següent
-
1
Catheter Management in Hemodialysis Patients per Anatole Besarab, Rahul Pandey
Publicat 2010Revisão -
2
-
3
-
4
-
5
-
6
-
7
-
8
Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients per Ajay Gupta, Vivian Lin, Carrie Guss, Raymond D. Pratt, T. Alp İkizler, Anatole Besarab
Publicat 2015Artigo -
9
-
10
Vascular access results from the Dialysis Outcomes and Practice Patterns Study (DOPPS): Performance against Kidney Disease Outcomes Quality Initiative (K/DOQI) Clinical Practice Gu... per Hugh C. Rayner, Anatole Besarab, Wendy Weinstock Brown, Alex Disney, Akira Saitō, Ronald L. Pisoni
Publicat 2004Artigo -
11
-
12
-
13
-
14
-
15
Comparative Effectiveness of Two Catheter Locking Solutions to Reduce Catheter-Related Bloodstream Infection in Hemodialysis Patients per Carol L. Moore, Anatole Besarab, Marie Ajluni, Vivek Soi, Edward L. Peterson, Laura E. Johnson, Marcus Zervos, Elizabeth M. Adams, Jerry Yee
Publicat 2014Artigo -
16
Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease per Anatole Besarab, Kristen K. Flaharty, A. J. Erslev, Jacqueline B. McCrea, Peter H. Vlasses, Fernando F. Corrales Medina, J. Jaime, Edward M Morris
Publicat 1992Artigo -
17
Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients per Anatole Besarab, Robert Provenzano, Joachim Hertel, Raja I. Zabaneh, Stephen J. Klaus, Tyson Lee, Robert Leong, Stefan Hemmerich, Kin-Hung P. Yu, Thomas B. Neff
Publicat 2015Artigo -
18
Recommended standards for reports dealing with arteriovenous hemodialysis accesses per Anton N. Sidawy, Richard Gray, Anatole Besarab, Mitchell L. Henry, Enrico Ascher, Michael Silva, Arnold Miller, Larry A. Scher, Scott O. Trerotola, Roger T. Gregory, Robert B. Rutherford, K. Craig Kent
Publicat 2002Revisão -
19
Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Rangin... per Robert Provenzano, Anatole Besarab, Steven Charles Wright, Sohan Dua, Steven Zeig, Peter Nguyen, Lona Poole, Khalil G. Saikali, Gopal Saha, Stefan Hemmerich, Lynda A. Szczech, K.H.P. Yu, Thomas B. Neff
Publicat 2016Artigo -
20
Peginesatide in Patients with Anemia Undergoing Hemodialysis per Steven Fishbane, Brigitte Schiller, Francesco Locatelli, Adrian Covic, Robert Provenzano, Andrzej Więcek, Nathan W. Levin, Mark Kaplan, Iain C. Macdougall, Carol Francisco, Martha Mayo, Krishna R. Polu, Anne‐Marie Duliège, Anatole Besarab
Publicat 2013Artigo
Eines de cerca:
Matèries relacionades
Medicine
Internal medicine
Anemia
Hemodialysis
Surgery
Intensive care medicine
Erythropoietin
Kidney disease
Randomized controlled trial
Dialysis
Gastroenterology
Pathology
Adverse effect
Clinical endpoint
Epoetin alfa
Hemoglobin
Alternative medicine
Arteriovenous fistula
Catheter
Confidence interval
Endocrinology
Hematocrit
Placebo
Vascular access
Disease
Erythropoiesis
Guideline
Iron deficiency
Urology
Biology